Coherus Oncology (CHRS) Receivables - Net (2013 - 2026)
Coherus Oncology (CHRS) posted Receivables - Net of $22.1 million for Q1 2026, up 23.85% sequentially from $17.8 million in Q4 2025, and down 63.52% YoY from $60.5 million in Q1 2025.
Coherus Oncology (CHRS) Receivables - Net (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Receivables - Net for 13 years, with the latest figure at $22.1 million in Q1 2026.
- Quarterly Receivables - Net fell 63.52% year-over-year to $22.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 million (down 63.52% YoY) and the FY2025 annual result came in at $17.8 million, down 84.0% from the prior year.
- Receivables - Net grew to $22.1 million in Q1 2026 per CHRS's latest filing, from $17.8 million in the prior quarter.
- Over five years, Receivables - Net peaked at $260.5 million in Q4 2023 and troughed at $5.1 million in Q2 2025.
- A 5-year average of $116.1 million and a median of $111.3 million in 2024 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2024 and 2025: Receivables - Net surged 148.33% in 2024, then sank 97.08% in 2025.
- Over 5 years, Receivables - Net stood at $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then tumbled by 57.27% to $111.3 million in 2024, then sank by 84.0% to $17.8 million in 2025, then gained by 23.85% to $22.1 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $22.1 million, $17.8 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.88 Mn |
| Jun 30, 2026 | 13.88 Mn |
| Mar 31, 2026 | 22.06 Mn |
| Mar 31, 2026 | 22.06 Mn |
| Dec 31, 2025 | 17.82 Mn |
| Dec 31, 2025 | 17.82 Mn |
| Sep 30, 2025 | 9.25 Mn |
| Sep 30, 2025 | 9.25 Mn |
| Jun 30, 2025 | 5.11 Mn |
| Jun 30, 2025 | 5.11 Mn |
| Mar 31, 2025 | 60.49 Mn |
| Mar 31, 2025 | 60.49 Mn |
| Dec 31, 2024 | 111.32 Mn |
| Dec 31, 2024 | 111.32 Mn |
| Sep 30, 2024 | 167.56 Mn |
| Sep 30, 2024 | 167.56 Mn |
| Jun 30, 2024 | 175.25 Mn |
| Jun 30, 2024 | 175.25 Mn |
| Mar 31, 2024 | 251.95 Mn |
| Mar 31, 2024 | 251.95 Mn |